| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 73846 |
cas:1639939-40-4 Mal-Val-Ala-PAB-PNP |
74 |
zyl |
2024-12-19 |
| 73847 |
MA-PEG8-VA-PAB-SG3199，ADC定制 |
88 |
wyh |
2024-12-19 |
| 73848 |
Acid-PEG4-Val-Cit-PAB-MMAE |
66 |
zyl |
2024-12-19 |
| 73849 |
MC-Val-Cit-PAB-Indibulin，cas:2055896-95-0，ADC定制 |
82 |
wyh |
2024-12-19 |
| 73850 |
cas:1096584-62-1 Mal-Val-Cit-PAB-PNP |
79 |
zyl |
2024-12-19 |
| 73851 |
cas:863971-53-3 Fmoc-Val-Cit-PAB-PNP |
79 |
zyl |
2024-12-19 |
| 73852 |
MC-Sq-Cit-PAB-Dolastatin10 ，cas:1941168-65-5，ADC定制 |
95 |
wyh |
2024-12-19 |
| 73853 |
Mal-PEG2-Val-Cit-PAB-OH ADC抗体偶联药物 |
85 |
zyl |
2024-12-19 |
| 73854 |
N3-PEG4-DYKDDDD-Doxorubicin，ADC定制 |
102 |
wyh |
2024-12-19 |
| 73855 |
MA-vc-PAB-DM1 cas:1464051-44-2 |
66 |
zyl |
2024-12-19 |
| 73856 |
DBCO-PEG4-VC-PAB-DMAE-Duocarmycin SA |
87 |
zyl |
2024-12-19 |
| 73857 |
VC-PAB-DMAE-PNU159682 ADC抗体偶联药物 |
82 |
zyl |
2024-12-19 |
| 73858 |
MC-GGFG-DX8951 cas:1600418-29-8 |
75 |
zyl |
2024-12-19 |
| 73859 |
DOTA-NGR NGR肽偶联1,4,7,10-四氮杂环十二烷-N,N’,N”,N”’-四乙酸(DOTA) |
90 |
h |
2024-12-19 |
| 73860 |
N3-PEG4-vc-PAB-Doxorubicin 叠氮PEG修饰维生素C-阿霉素的介绍 |
184 |
zyl |
2024-12-19 |
| 73861 |
DOTA-Ahx-(d-Lys6-GnRH1)DOTA偶联的d-Lys6-GnRH肽 |
88 |
h |
2024-12-19 |
| 73862 |
DOTA-porphyrin 双功能螯合剂DOTA偶联5-(对-氨基-丙烯-氧苯基)-10,15,20-三-(对-羧基-甲基-烯-氧苯基)卟啉 |
117 |
h |
2024-12-19 |
| 73863 |
VC-SECO DUBA analogue，ADC定制 |
92 |
wyh |
2024-12-19 |
| 73864 |
DOTA-H-Lys(Boc)-OH-SWCNTs 赖氨酸胺手柄功能化的单壁碳纳米管偶联DOTA螯合剂 |
86 |
h |
2024-12-19 |
| 73865 |
[DOTA-A1]-ZHER2:S1 抗HER2 ZHER2:S1亲和体分子缀合DOTA |
111 |
h |
2024-12-19 |
| 73866 |
Vc-MMAD cas:1401963-17-4的结构式 |
72 |
zyl |
2024-12-19 |
| 73867 |
DOTA-E(c(RGDfK))大环DOTA偶联双环肽E[c(RGDfK)] |
96 |
h |
2024-12-19 |
| 73868 |
CL2A-SN38，cas:1279680-68-0，ADC定制 |
159 |
wyh |
2024-12-19 |
| 73869 |
DOTA-gluBBN DOTA缀合铃蟾肽类似物 |
73 |
h |
2024-12-19 |
| 73870 |
DOTA-GSG-KCCYSL DOTA缀合物ErbB-2靶向肽KCCYSL |
147 |
h |
2024-12-19 |
| 73871 |
MC-MMAF ， cas:863971-19-1，ADC定制 |
111 |
wyh |
2024-12-19 |
| 73872 |
TCO-PEG4-Fmoc-Gly-Gly-Gly-ADC连接子 |
135 |
zyl |
2024-12-19 |
| 73873 |
模拟肽4-[2-(3,4,5,6-四氢嘧啶-2-基氨基)乙氧基]苯甲酰基-2-[N-(3-氨基-新戊-1-氨基甲酰基)]-氨乙基磺酰基-氨基-β-丙氨酸(IAC)缀合DOTA |
81 |
h |
2024-12-19 |
| 73874 |
DOTA-chCE7 DOTA标记的糖基化单克隆抗L1-CAM抗体chCE7 |
97 |
h |
2024-12-19 |
| 73875 |
Vc-MMAE， cas:646502-53-6，ADC定制 |
127 |
wyh |
2024-12-19 |
| 73876 |
Azido-PEG4-MMAE |
112 |
zyl |
2024-12-19 |
| 73877 |
cas:2055024-59-2，Fmoc-PEG2-Val-Cit-PAB-OH |
113 |
zyl |
2024-12-19 |
| 73878 |
Azide-PEG6-Val-Cit-PAB-PEG6- Biotin，ADC定制 |
114 |
wyh |
2024-12-19 |
| 73879 |
Ga-DOTA-(Asp)n 大环DOTA共轭(Asp)n肽 |
70 |
h |
2024-12-19 |
| 73880 |
cas:1807530-16-0，2-hydroxyethyl disulfide mono-Tosylate- ADC linker |
87 |
zyl |
2024-12-19 |
| 73881 |
DOTA偶联受体特异性肽 |
115 |
h |
2024-12-19 |
| 73882 |
聚乙二醇化DOTA-AHA基GdIII螯合物 PEGylated DOTA-based gadolinium(III) |
93 |
h |
2024-12-19 |
| 73883 |
PAMAM树状大分子DOTA缀合物 PAMAM–DOTA |
98 |
h |
2024-12-19 |
| 73884 |
ALD-tetra-EG-Osu的介绍 |
117 |
zyl |
2024-12-19 |
| 73885 |
SSTR2靶向肽Tyr(3)-奥曲肽(tate) |
215 |
h |
2024-12-19 |
| 73886 |
DOTA-D-Phe(1)-Tyr(3)-Octreotide |
89 |
h |
2024-12-19 |
| 73887 |
cas:55750-63-5，Mal-heptanoic NHS ester |
108 |
zyl |
2024-12-19 |
| 73888 |
DOTA-Fab-PEG24-EGF DOTA-PEG修饰曲妥珠单抗Fab片段偶联表皮生长因子 |
95 |
h |
2024-12-19 |
| 73889 |
cas:663599-10-8，DMAC-SPP |
103 |
zyl |
2024-12-19 |
| 73890 |
多甲基化的1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)配体 |
141 |
h |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询